| Issue Date | Title | Author(s) |
| 3-Aug-2019 | Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis | Anne Julienne Genuino; Usa Chaikledkaew; Due Ong The; Thanyanan Reungwetwattana; Ammarin Thakkinstian; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Mahidol University |
| 1-May-2019 | Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study | Caicun Zhou; Sang We Kim; Thanyanan Reungwetwattana; Jianying Zhou; Yiping Zhang; Jianxing He; Jin Ji Yang; Ying Cheng; Se Hoon Lee; Lilian Bu; Tingting Xu; Li Yang; Chao Wang; Ting Liu; Peter N. Morcos; You Lu; Li Zhang; Sun Yat-Sen University Cancer Center; Tongji University; Zhejiang Cancer Hospital; West China School of Medicine/West China Hospital of Sichuan University; Guangdong General Hospital; Asan Medical Center; SungKyunKwan University, School of Medicine; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Guangzhou Medical University; F. Hoffmann-La Roche AG; Zhejiang University; Roche Innovation Center; Jilin Cancer Hospital; Roche Pharma Development |
| 2016 | ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy | Pimpin Incharoen; Thanyanan Reungwetwattana; Sakditad Saowapa; Kaettipong Kamprerasart; Duangjai Pangpunyakulchai; Lalida Arsa; Artit Jinawath; Mahidol University. Faculty of Medicine Ramathibodi Hospital. Department of Pathology |
| 1-Mar-2020 | Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC | Wan Ling Tan; Kevin L.M. Chua; Chia Chi Lin; Victor H.F. Lee; Lye Mun Tho; Anthony W. Chan; Gwo Fuang Ho; Thanyanan Reungwetwattana; James C. Yang; Dong Wan Kim; Ross A. Soo; Yong Chan Ahn; Hiroshi Onishi; Myung Ju Ahn; Tony S.K. Mok; Daniel S.W. Tan; Fan Yang; Peking University People's Hospital; National Taiwan University Hospital; National Cancer Centre, Singapore; National University Hospital, Singapore; Seoul National University Hospital; SungKyunKwan University, School of Medicine; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; University of Malaya Medical Centre; University of Yamanashi; The University of Hong Kong; Chinese University of Hong Kong; Beacon Hospital |
| 22-Apr-2011 | Chemotherapy for non-small-cell lung carcinoma: From a blanket approach to individual therapy | Thanyanan Reungwetwattana; Matthew J. Eadens; Julian R. Molina; Mahidol University; Mayo Medical School |
| 20-Nov-2018 | CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer | Thanyanan Reungwetwattana; Kazuhiko Nakagawa; Byoung Chul Cho; Manuel Cobo; Eun Kyung Cho; Alessandro Bertolini; Sabine Bohnet; Caicun Zhou; Ki Hyeong Lee; Naoyuki Nogami; Isamu Okamoto; Natasha Leighl; Rachel Hodge; Astrid McKeown; Andrew P. Brown; Yuri Rukazenkov; Suresh S. Ramalingam; Johan Vansteenkiste; Yonsei Cancer Center; Chungbuk National University Hospital; Gachon University; Tongji University; KU Leuven– University Hospital Leuven; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Universitätsklinikum Schleswig-Holstein Campus Lübeck; National Hospital Organization, Japan; Hospital Regional Universitario Carlos Haya; Kyushu University; Ontario Cancer Institute University of Toronto; AstraZeneca; Emory University School of Medicine; Kindai University; Hospital of Sondrio |
| 21-Nov-2019 | Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines | Anne Julienne Genuino; Usa Chaikledkaew; Anna Melissa Guerrero; Thanyanan Reungwetwattana; Ammarin Thakkinstian; Department of Health Manila; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Mahidol University |
| 1-Jan-2011 | Current and emerging therapies in peripheral T-cell lymphoma: Focus on pralatrexate | Thanyanan Reungwetwattana; Sylvia Jaramillo; Julian R. Molina; Mayo Medical School; Mahidol University |
| 1-Jan-2018 | Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients | Chalirmporn Atasilp; Pichai Chansriwong; Ekapob Sirachainan; Thanyanan Reungwetwattana; Apichaya Puangpetch; Santirhat Prommas; Suwannee Sirilerttrakul; Budsaba Rerkarmnuaychoke; Sansanee Wongwaisayawan; Chonlaphat Sukasem; Faculty of Medicine, Ramathibodi Hospital, Mahidol University |
| 1-Jan-2015 | MET exon 14 deletion (METex14): Finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval | Thanyanan Reungwetwattana; Sai Hong Ignatius Ou; Mahidol University; UCI School of Medicine |
| 1-Jul-2012 | Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC) | Thanyanan Reungwetwattana; Saravut J. Weroha; Julian R. Molina; Mahidol University; Mayo Clinic |
| 2-Jan-2020 | Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | Suresh S. Ramalingam; Johan Vansteenkiste; David Planchard; Byoung Chul Cho; Jhanelle E. Gray; Yuichiro Ohe; Caicun Zhou; Thanyanan Reungwetwattana; Ying Cheng; Busyamas Chewaskulyong; Riyaz Shah; Manuel Cobo; Ki Hyeong Lee; Parneet Cheema; Marcello Tiseo; Thomas John; Meng Chih Lin; Fumio Imamura; Takayasu Kurata; Alexander Todd; Rachel Hodge; Matilde Saggese; Yuri Rukazenkov; Jean Charles Soria; Yonsei Cancer Center; Jilin Provincial Cancer Hospital; Shanghai Pulmonary Hospital; Chang Gung University College of Medicine; KU Leuven– University Hospital Leuven; Institut de Cancerologie Gustave Roussy; Kansai Medical University; Université Paris-Sud; National Cancer Center Hospital; University of Toronto; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Hospital Regional Universitario Carlos Haya; Università degli Studi di Parma, Facoltà di Medicina e Chirurgia; Chungbuk National University, College of Medicine; Austin Health; Moffitt Cancer Center; Maidstone Hospital; AstraZeneca; Emory University School of Medicine; Chiang Mai University; Osaka International Cancer Institute |
| 1-Jan-2015 | A phase i study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors | Nuttapong Ngamphaiboon; Grace K. Dy; Wen Wee Ma; Yujie Zhao; Thanyanan Reungwetwattana; Dawn Depaolo; Yi Ding; William Brady; Gerald Fetterly; Alex A. Adjei; Roswell Park Cancer Institute; Mahidol University |
| 20-Jan-2018 | Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma | Milind Javle; Maeve Lowery; Rachna T. Shroff; Karl Heinz Weiss; Christoph Springfeld; Mitesh J. Borad; Ramesh K. Ramanathan; Lipika Goyal; Saeed Sadeghi; Teresa Macarulla; Anthony El-Khoueiry; Robin Kate Kelley; Ivan Borbath; Su Pin Choo; Do Youn Oh; Philip A. Philip; Li Tzong Chen; Thanyanan Reungwetwattana; Eric Van Cutsem; Kun Huei Yeh; Kristen Ciombor; Richard S. Finn; Anuradha Patel; Suman Sen; Dale Porter; Randi Isaacs; Andrew X. Zhu; Ghassan K. Abou-Alfa; Tanios Bekaii-Saab; National Cheng Kung University Hospital; Barbara Ann Karmanos Cancer Institute; National Cancer Centre, Singapore; KU Leuven– University Hospital Leuven; UCSF Helen Diller Family Comprehensive Cancer Center; Mayo Clinic Scottsdale-Phoenix, Arizona; National Taiwan University College of Medicine; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Keck School of Medicine of USC; University of Texas MD Anderson Cancer Center; Seoul National University; Cliniques Universitaires Saint-Luc, Brussels; Hospital Universitari Vall d'Hebron; Memorial Sloan-Kettering Cancer Center; David Geffen School of Medicine at UCLA; Ohio State University; Universitätsklinikum Heidelberg; Massachusetts General Hospital Cancer Center; Novartis Pharmaceuticals Corporation |
| 1-May-2018 | Progress in the Management of Malignant Pleural Mesothelioma in 2017 | Amanda J. McCambridge; Andrea Napolitano; Aaron S. Mansfield; Dean A. Fennell; Yoshitaka Sekido; Anna K. Nowak; Thanyanan Reungwetwattana; Weimin Mao; Harvey I. Pass; Michele Carbone; Haining Yang; Tobias Peikert; Zhejiang Cancer Hospital; University of Leicester; Università degli Studi di Roma La Sapienza; NYU Langone Medical Center; University of Western Australia; Aichi Cancer Center Hospital and Research Institute; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; University of Hawaii at Manoa; Mayo Clinic; Zhejiang Key Laboratory of Diagnosis and Treatment Technology of Thoracic Oncology |
| 1-Jan-2017 | The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable | Thanyanan Reungwetwattana; Ying Liang; Viola Zhu; Sai Hong Ignatius Ou; Mahidol University; Sun Yat-Sen University Cancer Center; VA Medical Center; UCI Medical Center |
| 1-Jan-2019 | Role of BIM deletion polymorphism and BIM expression as predictive biomarkers to maximize the benefit of EGFR-TKI treatment in EGFR-Positive NSCLC | Pimpin Incharoen; C. Charonpongsuntorn; Chanchai Sakditad Saowapa; Ekaphop Sirachainan; Thitiya Dejthevaporn; Kaettipong Kampreasart; Narumol Trachu; Dittapol Muntham; Thanyanan Reungwetwattana; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Mahidol University; Srinakharinwirot University; Rajamangala University of Technology Suvarnabhumi |
